Get started
Author

Trevor G. Levin

Observed names: Levin, Trevor, Levin, Trevor G., Levin, Trevor Gilpin, Trevor G Levin, Trevor Levin
ORCID: 0000-0003-1323-1126
Observed ORCID: 0000-0003-1323-1126
OpenAlex ID: A5058697018
Characterization of the Intestinal Cancer Stem Cell Marker CD166 in the Human and Mouse Gastrointestinal Tract
2010 · Trevor G. Levin, Anne E. Powell, et al. · Gastroenterology · 191
The Role of Colorectal Cancer Stem Cells in Metastatic Disease and Therapeutic Response
2011 · Eric C. Anderson, Crystal Hessman, et al. · Cancers · 79
PDF
IL-10 and integrin signaling pathways are associated with head and neck cancer progression
2016 · Sophia Bornstein, Mark Schmidt, et al. · BMC Genomics · 46
PDF
Cell Adhesion Molecule CD166/ALCAM Functions Within the Crypt to Orchestrate Murine Intestinal Stem Cell Homeostasis
2017 · Nicholas R. Smith, Paige S. Davies, et al. · Cellular and Molecular Gastroenterology and Hepatology · 36
PDF
MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection
2018 · Dmitri V. Rozanov, Nikita D. Rozanov, et al. · Journal of Proteomics · 35
Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
2023 · Keyan Salari, Debasish Sundi, et al. · Clinical Cancer Research · 29
PDF
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec
2024 · Vikram M. Narayan, Come Tholomier, et al. · European Urology Oncology · 24
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
2025 · Marie-Pier St-Laurent, Parminder Singh, et al. · European Urology · 20
Urinary Comprehensive Genomic Profiling Correlates Urothelial Carcinoma Mutations with Clinical Risk and Efficacy of Intervention
2022 · Vincent T. Bicocca, Kevin G. Phillips, et al. · Journal of Clinical Medicine · 16
PDF
TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response
2015 · Dmitri Rozanov, Anton Cheltsov, et al. · PLoS ONE · 15
PDF
Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy
2023 · Goran Rac, Hiten D. Patel, et al. · Molecular Oncology · 14
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer
2024 · David J. McConkey, Brian C. Baumann, et al. · Bladder Cancer · 3
PDF
Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605.
2024 · Marie-Pier St-Laurent, Melissa Plets, et al. · Journal of Clinical Oncology · 2
Urinary minimal residual disease detection predicts recurrence in BCG-unresponsive NIMBC and quantifies molecular response to nadofaragene firadenovec.
2024 · Vikram M Narayan, Come Tholomier, et al. · Journal of Clinical Oncology · 2
PDF
Urine Tumor DNA Testing Identifies Recurrence and Monitors Therapy Response in Patients With High-Risk Nonmuscle-Invasive Bladder Cancer Receiving Intravesical Bacillus Calmette-Guérin
2026 · Henning Bahlburg, Moritz Maas, et al. · The Journal of Urology · 1
T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer
2025 · Johanna M Schafer, No-Joon Song, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Ip02-06 the Role of the Uroamp Mrd in Predicting Recurrence in High-risk Non-muscle Invasive Bladder Cancer Undergoing Bcg
2025 · Henning Bahlburg, Moritz Maas, et al. · The Journal of Urology · 1
Clinical utility of urinary comprehensive genomic profiling in diagnosing metachronous upper tract urothelial carcinoma: a case report
2023 · Paul M. Yonover, Ceressa T. Ward, et al. · Frontiers in Urology · 1
PDF
Mp22-19 Urinary Comprehensive Genomic Profiling Predicts Urothelial Cancer up to 12 Years Ahead of Clinical Diagnosis. an Expanded Analysis of the Golestan Cohort Study
2023 · Yair Lotan, Keyan Salari, et al. · The Journal of Urology · 1
Mp54-09 Urine Comprehensive Genomic Profiling Predicts Recurrence in Patients With Non-muscle Invasive Bladder Cancer Treated With Intravesical Therapy
2022 · Goran Rac, Shalin Desai, et al. · The Journal of Urology · 1
Pd12-10 Urine Comprehensive Genomic Profiling of Urothelial Carcinoma Patients Undergoing Intravesical Therapy Enables Detection of Actionable Dna Mutations Associated With Drug Response and Risk Stratification
2022 · Goran Rac, Shalin Desai, et al. · The Journal of Urology · 1
Comprehensive genomic profiling of urine DNA for urothelial carcinoma detection and risk prediction.
2022 · Keyan Salari, Jason J. Lee, et al. · Journal of Clinical Oncology · 1
Clinical validation of an ultra-deep next generation DNA sequencing approach for the detection of bladder cancer in the urine.
2018 · Jason Ablat, Theresa M. Koppie, et al. · Journal of Clinical Oncology · 1
Integrated Urine and Plasma DNA Analysis for Molecular Staging of Upper Tract Urothelial Carcinoma
2026 · Maximilian Pallauf, Stephan Bronimann, et al. · European Urology Oncology
PDF
Performance of Urine Tumor DNA Detection in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Repeat Transurethral Resection
2026 · Jay Ogunkeye, Eugene Shkolyar, et al. · European Urology Focus
Works count: 73
Citation count: 521
H-index: 11
I10-index: 11
Year
Topic
Type